Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Gormley

Physical Medicine & Rehabilitation Saint Paul, MN Medical Doctor

NPI 1558392068 CMS profile 834495

200 University Ave E, Saint Paul, MN 55101

Open in the dashboard

General payments

$118,043

97 records reported · program years 2019–2025

Research payments

$1,025

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$60,254 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Mark Gormley of Saint Paul, MN is reported in the CMS Open Payments database as having received $118,043 across 97 general payments and $1,025 in research payments paid to them. Separately, studies naming them as principal investigator received $60,254 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,187 6
2024 General $1,320 2
2023 General $38,136 30
2022 General $10,284 12
2021 General $5,341 4
2021 Research $1,025 1
2020 General $10,285 5
2019 General $43,489 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Gormley
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Mark Gormley were reported at $9,187. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Mark Gormley Physical Medicine & Rehabilitation median Middle half National median
2019 $43,489 $133 $45–$390 $163
2020 $10,285 $88 $29–$272 $114
2021 $5,341 $116 $33–$360 $132
2022 $10,284 $123 $40–$378 $149
2023 $38,136 $131 $43–$396 $160
2024 $1,320 $141 $45–$409 $164
2025 $9,187 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ipsen Biopharmaceuticals, Inc $61,297 31 payments
  2. Allergan Inc. $35,197 33 payments
  3. AbbVie, Inc. $12,434 12 payments
  4. Ipsen Innovation $5,474 3 payments
  5. Neurocrine Biosciences, Inc. $2,026 15 payments
  6. PTC Therapeutics, Inc. $1,400 1 payment
  7. Medtronic, Inc. $216 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $60,585 21 payments
  2. Consulting Fee $37,040 12 payments
  3. Travel and Lodging $15,914 30 payments
  4. Food and Beverage $2,254 32 payments
  5. Honoraria $2,250 2 payments
Products named General payments · program years 2019–2025
  1. DYSPORT $66,771 34 payments
  2. BOTOX Neuroscience $27,623 25 payments
  3. BOTOX Neuroscience $19,284 15 payments
  4. SYNCHROMEDII $195 1 payment
  5. BOTOX Hyperhydrosis $152 3 payments
  6. BOTOX Spasticity $22 1 payment
  7. Ascenda $21 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $1,025 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

79

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$3,922

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

0%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 13 $1,463
Baclofen Generic 26 $1,310
Glycopyrrolate Generic 12 $557
Diazepam Generic 14 $343
Trihexyphenidyl Hcl Generic 14 $249

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$12,923

Medicare's payments for the services billed

Medicare patients

38

Average age 34

Services billed

230

19 women, 19 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 0%
Heart failure 0%
Ischemic heart disease 0%
Atrial fibrillation 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DYSPORT
  • Ipsen Biopharmaceuticals, Inc $1,125
$1,125 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

98 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record